- Home
- PSN vs ROIV Comparison
PSN vs ROIV Comparison
Compare PSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSN
- ROIV
- Stock Information
- Founded
- PSN 1944
- ROIV 2014
- Country
- PSN United States
- ROIV United Kingdom
- Employees
- PSN N/A
- ROIV N/A
- Industry
- PSN EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PSN Technology
- ROIV Health Care
- Exchange
- PSN Nasdaq
- ROIV Nasdaq
- Market Cap
- PSN 8.6B
- ROIV 8.6B
- IPO Year
- PSN 2019
- ROIV N/A
- Fundamental
- Price
- PSN $81.44
- ROIV $15.09
- Analyst Decision
- PSN Strong Buy
- ROIV Strong Buy
- Analyst Count
- PSN 12
- ROIV 9
- Target Price
- PSN $88.91
- ROIV $19.94
- AVG Volume (30 Days)
- PSN 1.0M
- ROIV 8.2M
- Earning Date
- PSN 10-29-2025
- ROIV 11-11-2025
- Dividend Yield
- PSN N/A
- ROIV N/A
- EPS Growth
- PSN 23.64
- ROIV N/A
- EPS
- PSN 2.23
- ROIV N/A
- Revenue
- PSN $6,683,116,000.00
- ROIV $23,233,000.00
- Revenue This Year
- PSN N/A
- ROIV N/A
- Revenue Next Year
- PSN $5.98
- ROIV $248.22
- P/E Ratio
- PSN $36.59
- ROIV N/A
- Revenue Growth
- PSN 9.22
- ROIV N/A
- 52 Week Low
- PSN $54.56
- ROIV $8.73
- 52 Week High
- PSN $114.68
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- PSN 60.52
- ROIV 78.02
- Support Level
- PSN $74.33
- ROIV $13.81
- Resistance Level
- PSN $76.92
- ROIV $16.05
- Average True Range (ATR)
- PSN 2.27
- ROIV 0.50
- MACD
- PSN 0.35
- ROIV 0.22
- Stochastic Oscillator
- PSN 79.48
- ROIV 77.14
About PSN Parsons Corporation
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.